false
Catalog
2023 Targeted Therapies of Lung Cancer Meeting (Po ...
P1.18. Phase II Trial of Regorafenib and Oral Meth ...
P1.18. Phase II Trial of Regorafenib and Oral Methotrexate in Previously Treated Advanced KRAS Mutant Non-Small Cell Lung Cancer - 2
Back to course
Pdf Summary
This study examined the prevalence and genomic landscape of fibroblast growth factor receptor (FGFR) alterations in metastatic non-small cell lung cancer (mNSCLC), including patients who had received epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) treatment. The researchers analyzed de-identified records of patients who were sequenced using the Tempus xT assay. <br /><br />The study found that FGFR alterations were present in both treatment-naive and EGFR TKI-treated patients. The prevalence of FGFR alterations was around 13-14% in both groups. Copy number losses were the predominant type of FGFR alteration, accounting for 85% in treatment-naive patients and 93% in EGFR TKI-treated patients. The TACC3-FGFR3 fusion pair was detected in a small number of patients in both groups.<br /><br />FGFR2 and FGFR3 alterations were the most common FGFR alterations in both treatment-naive and EGFR TKI-treated patients. Additionally, the analysis identified novel FGFR fusions.<br /><br />The findings suggest that FGFR alterations may be a potential therapeutic target in mNSCLC, particularly in cases of EGFR TKI resistance. Further research is needed to determine if targeting FGFR alterations can provide therapeutic benefits.<br /><br />The study provides important insights into the prevalence and genomic landscape of FGFR alterations in mNSCLC. Understanding these alterations is critical for developing targeted therapies and improving treatment outcomes for patients with EGFR TKI resistance.
Asset Subtitle
Jacqueline Aredo, Stanford Cancer Institute, United States
Meta Tag
Speaker
Jacqueline Aredo, Stanford Cancer Institute, United States
Topic
Poster Listing
Keywords
fibroblast growth factor receptor alterations
metastatic non-small cell lung cancer
epidermal growth factor receptor tyrosine kinase inhibitor
Tempus xT assay
treatment-naive patients
EGFR TKI-treated patients
copy number losses
TACC3-FGFR3 fusion pair
FGFR2 alterations
FGFR3 alterations
×
Please select your language
1
English